Clin2
NCT06207370Possibly a fitRecruiting

Tafenoquine plus standard care for babesiosis

Babesiosis

Treatments studied

Part of Infections clinical trials.

This study tests whether adding the oral drug tafenoquine to standard care works better than standard care plus a placebo for treating babesiosis, a tick-borne illness. You must be hospitalized with active symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
33 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older and have a confirmed Babesia infection.
  • You are currently hospitalized for babesiosis treatment and will stay in the hospital for at least the first few days of the study.
  • You are willing to take oral medications and complete all study visits and assessments.
  • You have not taken azithromycin or atovaquone in the past year to treat babesiosis.
  • You are not pregnant and will use effective birth control if you could become pregnant.
  • You have no other serious illnesses or allergies that would make it unsafe to take the study drug.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06656351Recruiting· Phase 2
Study of tafenoquine for chronic babesiosis with fatigue

This study tests an oral medication, tafenoquine, to see if it helps people with chronic babesiosis who have ongoing fatigue and other symptoms. It aims to find a better treatment for this tick-borne infection that keeps coming back.

New York, New York
NCT06148792Recruiting· Phase 3
Testing a new dose of tafenoquine for vivax malaria

This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.

Manaus
NCT07373743Not yet recruiting· Early Phase 1
Study of tafenoquine in healthy adults

This study tests how the body processes a single dose of the antimalarial drug tafenoquine in healthy adults. It will help doctors understand how the drug works and how it is broken down, which may lead to better ways to prevent malaria.

East Syracuse, New York
NCT07060794Not yet recruiting· Phase 4
Preventing malaria relapse with tafenoquine

This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.

NCT07430592Not yet recruiting· Phase 2
Study of SJ733 and Tafenoquine for P. Vivax Malaria Cure

This trial tests a two-drug combination to safely and quickly clear all stages of P. vivax malaria from your body. You must have confirmed vivax malaria, be within a certain weight range, and agree to hospital stay and follow-up visits over 6 months.

Iquitos, Loreto
NCT04704999Recruiting· Phase 4
Testing the right tafenoquine dose for malaria prevention

This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.

Siem Reap

Hear when a new Babesiosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.